AZD5305: Clinical Trials

3 trials of AZD5305, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 active not recruiting. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Recruiting 2, Active not recruiting 1

Follow AZD5305: new trials by email Literature Review of AZD5305 trials Research Report on AZD5305

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone - Prostate Cancer
Phase 3RecruitingAstraZeneca7002025-08-062026-10-14
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Saruparib (AZD5305), Camizestrant, Abemaciclib - Advanced Breast Cancer
Phase 3RecruitingAstraZeneca7882024-08-012026-10-30
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Saruparib, Placebo, Abiraterone Acetate - Metastatic Castration-Sensitive Prostate Cancer
Phase 3Active not recruitingAstraZeneca18982023-11-212026-11-10

Conditions studied

Prostatic Neoplasms (2)

Sponsors

AstraZeneca (3)

Countries

Australia (3)  ·  Austria (3)  ·  Brazil (3)  ·  Canada (3)  ·  Chile (3)  ·  China (3)  ·  France (3)  ·  Germany (3)  ·  Hungary (3)  ·  India (3)  ·  Italy (3)  ·  Japan (3)  ·  Malaysia (3)  ·  Peru (3)  ·  Poland (3)

Top investigators

Arun Azad, MD (1)  ·  Kim Nguyen Chi, MD (1)

Results publications

PMID 41979035

NIH funding

2023 (1)